---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-261693"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2026-06-08T20:05:15+00:00"
generated_at: "2026-06-08T20:06:29.172591+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics 2026 annual meeting results: all director nominees and proposals approved

## Summary
- John Evans, John Maraganore, and Christi Shaw elected as Class III directors with 71.7M, 64.8M, and 65.7M votes for respectively.
- Ratification of Deloitte as auditor for FY2026 passed with 85.8M votes for, 165.7K against.
- Advisory say-on-pay resolution approved with 71.5M for, 985.1K against.
- Broker non-votes totaled approximately 13.4M shares for director elections and say-on-pay.

## SEC filing metadata
- accession: 0001193125-26-261693
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2026-06-08T20:05:15+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/0001193125-26-261693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/beam-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-261693
- JSON: https://secwatch.observer/filing/0001193125-26-261693.json
- Plain text: https://secwatch.observer/filing/0001193125-26-261693.txt

## Key facts
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-03 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes: For Against Abstentions Broker Non-Votes 71,546,749 985,066 273,533 13,419,659
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/0001193125-26-261693-index.htm
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was ratified, based on the following votes: For Against Abstentions 85,754,272 165,746 304,989
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/0001193125-26-261693-index.htm
- Shareholder Votes
  Beam Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-03
  source text: Proposal 1 – The following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes: Nominee For Against Abstentions Broker Non-Votes John Evans 71,684,417 864,042 256,889 13,419,659 John Maraganore, Ph.D. 64,846,080 7,701,591 257,677 13,419,659 Christi Shaw 65,652,959 6,893,102 259,287 13,419,659
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312526261693/0001193125-26-261693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.